

Original Article  
Pharmacology,  
Drug Therapy & Toxicology



# Safety and Efficacy of Off-label and Unlicensed Medicines in Children

Ji-Hyun Lee ,<sup>1</sup> Hyo-Jin Byon ,<sup>2</sup> Seungeun Choi ,<sup>1</sup> Young-Eun Jang ,<sup>1</sup>  
Eun-Hee Kim ,<sup>1</sup> Jin-Tae Kim ,<sup>1</sup> and Hee-Soo Kim <sup>1</sup>

<sup>1</sup>Department of Anesthesiology and Pain Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea

<sup>2</sup>Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine, Seoul, Korea

OPEN ACCESS

Received: Apr 17, 2018

Accepted: Jun 14, 2018

Address for Correspondence:

Hee-Soo Kim, MD, PhD

Department of Anesthesiology and Pain Medicine, Seoul National University Hospital, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea.

E-mail: dami0605@snu.ac.kr

© 2018 The Korean Academy of Medical Sciences.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<https://creativecommons.org/licenses/by-nc/4.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ORCID iDs

Ji-Hyun Lee

<https://orcid.org/0000-0002-8384-8191>

Hyo-Jin Byon

<https://orcid.org/0000-0002-5400-6155>

Seungeun Choi

<https://orcid.org/0000-0002-9762-2492>

Young-Eun Jang

<https://orcid.org/0000-0002-7511-4104>

Eun-Hee Kim

<https://orcid.org/0000-0003-0697-1935>

Jin-Tae Kim

<https://orcid.org/0000-0002-3738-0081>

Hee-Soo Kim

<https://orcid.org/0000-0002-2661-7944>

## ABSTRACT

**Background:** The aim of this study was to explore the use of off-label/unlicensed drugs to confirm the safety and efficacy of their prescription in children in Korea.

**Methods:** In this retrospective study, we analyzed data of patients who received any of the 32 drugs between January–December 2014 in tertiary hospitals in Korea, including demographics, diagnoses, reasons for the medication, administration route, and details of adverse drug reactions. Additionally, the mortality in the cohort was assessed. The primary outcomes were efficacy and safety, including mortality, of these drugs in pediatric patients. The secondary outcomes were the current statuses of the use of off-label/unlicensed drugs in two centers.

**Results:** Totally, 5,130 prescriptions were found in 2,779 patients. Age (73.5%) and indication (11.7%) were the most frequent reasons for prescriptions being off-labeled/unlicensed. Approximately 88% of the prescriptions were effective, and 19% of the patients developed adverse drug reactions. The number of prescriptions was significantly higher in children with adverse drug reactions than it was in those without (2.8 vs. 1.5;  $P < 0.001$ ). The number of prescribed off-label/unlicensed medicines and age at prescription were independently associated with adverse drug events (odds ratio, 1.55 and 1.1;  $P < 0.001$  and 0.034, respectively).

**Conclusion:** Children are still prescribed medicines that are not authorized in terms of age, weight, indications, or routes of administration. Therefore, many old products require re-assessment of authorization. More prospective clinical studies should be performed to confirm the efficacy and safety of drugs in the pediatric population.

**Keywords:** Adverse Drug Reaction; Drugs; Off-label Use; Pediatrics

## INTRODUCTION

The safety and efficacy of drugs, human derived products, or medical devices in clinical practice should be guaranteed. For physicians, the so-called ‘labelling (or licensing)’ is the one of the guidelines for the use of such drugs or medical devices based on evidence of safety and efficacy. However, in many clinical situations, drugs are more widely used than their approved indications, if they are deemed helpful to patients. In the pediatric population, many drugs used are ‘off-labeled’ or ‘unlicensed’ because labelling of most drugs is focused

**Funding**

This research was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health and Welfare, Republic of Korea (Grant Number: HC15C1523).

**Disclosure**

The authors have no potential conflicts of interest to disclose.

**Author Contributions**

Conceptualization: Kim HS. Data curation: Lee JH, Byon HJ, Choi S, Jang YE, Kim EH, Kim JT. Formal analysis: Lee JH. Investigation: Byon HJ, Jang YE, Kim EH. Writing - original draft: Lee JH. Writing - review & editing: Kim HS.

on their use in adults, and it is difficult to conduct clinical trials to assess the safety and efficacy of certain medicines with the approval of the regulatory bodies, in such vulnerable population.<sup>1</sup>

Off-labeled/unlicensed use of medicines includes drug administration that varies from the label in terms of indications, doses, age, and routes of administration. A previous study reported that among 2,262 drug prescriptions administered to 624 children in five European hospitals, 1,036 (46%) were either off-labeled or unlicensed; and 67% of the patients (n = 421) received at least one such prescription.<sup>2</sup> Off-labeled or unlicensed prescription is inevitable; however, there are great concerns that the safety and efficacy of drugs depend on the experience of the clinician and are not scientifically approved. The off-labeled/unlicensed use of medications was implicated in adverse drug reactions in children; therefore, off-labeled/unlicensed drugs should be prescribed cautiously when the benefits exceed the risks.<sup>3</sup> However, to ensure the safety and efficacy of such medications in pediatric patients, efforts are needed at several levels such as governments, companies, health care providers, and parents.<sup>4,5</sup> It is important to assess the scale of off-labeled/unlicensed use of drugs or medical devices in children in real clinical practice. It could provide the information regarding the safety and efficacy of off-labeled/unlicensed use of drugs or medical devices.

In this study, we explored the off-labeled/unlicensed drug use in tertiary hospitals in children to assess the safety and efficacy of drugs and to obtain detailed information of such prescription use in children by reviewing the prescriptions and their efficacy and adverse drug reaction.

## METHODS

### Study population

Pediatric patients who were admitted to the hospitals between January–December 2014 and received off-labeled/unlicensed drugs were enrolled. Patients who were aged > 18 years and lost to follow-up were excluded.

### List of drugs

The off-labeled/unlicensed drugs were determined based on the information from the library of Ministry of Food and Drug Safety (MFDS) of Korea. We classified the use of drugs as off-labeled/unlicensed in following cases: dose or frequency was higher than approved, the medicine was not approved for the weight or age of the patient, the indication not approved, the route of administration not approved, and unlicensed/extemporaneous product used.

A large number of medicines are used in the clinical setting; we selected a list of drugs before reviewing the electronic medical records (EMRs). We performed a survey amongst the staffs of the tertiary pediatric hospital to identify the drugs that were mostly prescribed as off-labeled/unlicensed and needed to be changed to be labeled as soon as possible. We then chose 32 prescribed off-labeled/unlicensed drugs (**Table 1**). The efficacy of each drug was assessed based on whether the expected effect of the drug was observed. To assess the safety, we evaluated not only the reported adverse drug reactions but also events that occurred immediately after the administration of such drugs. Adverse drug reaction was defined as follows, according to a previous report<sup>6</sup>: an appreciably harmful or unpleasant reaction, resulting from drug administration.

**Table 1.** A list of 32 prescribed drugs and their information including efficacy and safety variables

Drug name	Age or weight limitation	Efficacy variables	Safety variables
Bisoprolol	18 yr	Blood pressure control/treatment of heart failure	Bradycardia/hypotension
Carbidopa/L-dopa	18 yr	Improved neurologic symptoms/decreased prolactin level/for L-dopa test	Abnormal movement/nausea/vomiting/hypotension
Carvedilol	18 yr	Blood pressure control/treatment of heart failure	Bradycardia/hypotension
Ciprofloxacin	18 yr	Reduced length of hospital stay/decrease in infectious complications	Abnormal findings in cartilage and bone/gait disorder
Clobazam	3 yr	Decreased seizure activity	Oversedation/increased secretion
Dexmedetomidine	18 yr	Adequate sedation/analgesia	Hypertension/hypotension/bradycardia
Domperidone maleate	35 kg	Relief of nausea and vomiting	Abnormality in electrocardiogram/central nerve system abnormality
Dopamine	18 yr	Improved cardiac function/treated hypotension/increased urine output	Arrhythmia/peripheral ischemia/nausea and vomiting/abdominal distension
Enalapril	18 yr	Blood pressure control/improved cardiac function/decreased proteinuria	Cough/hyperkalemia/neutropenia/decreased kidney function
Esomeprazole magnesium trihydrate	12 yr	Improved symptoms of gastric ulcer	Pancytopenia/liver function abnormalities
Fentanyl	2 yr	Analgesia	Nausea or vomiting/chest tightness/itching/decreased respiratory rate
Fluconazole	6 mon	Treatment of candida infection	Pancytopenia/abnormality in electrocardiogram
Ganciclovir	18 yr	Treatment of cytomegalovirus	Pancytopenia/decreased kidney function
Lansoprazole	18 yr	Improved symptom of gastric ulcer	Pancytopenia/liver function abnormality
Levetiracetam	Injection, 16 yr; tablets, 4 yr; syrup 1 mon	Decreased seizure activity	Gait disorder/arrhythmia/decreased respiratory rate
Levocetirizine		Relief of skin rash	Fever/diarrhea/vomiting/middle ear infection
Levofloxacin	18 yr	Subsided fever/improved chest X-ray findings in mycoplasma pneumonia	Abnormality of cartilage/gait disorder
Losartan	18 yr	Blood pressure control/decreased proteinuria	Hypotension/kidney function abnormality
Metoclopramide	1 yr	Improved gastrointestinal symptom	Pancytopenia/liver function abnormalities/diarrhea
Mosapride	18 yr	Decrease in nausea or vomiting	Extrapyramidal symptom
Octreotide	18 yr	Maintenance of blood glucose level	Nausea, vomiting/abdominal distension
Pamidronate	18 yr	Increased bone density	Fever/hypercalcemia
Propacetamol	18 yr	Subsided fever/analgesia	Allergic reaction/nausea, vomiting/dizziness
Propofol	For general anesthesia, 3 yr; for sedation, 16 yr	Sedation, hypnosis	Hypotension/apnea/hypoxia
Ramosetron	18 yr	Reduced nausea or vomiting	Dizziness/drowsiness/headache/fever, chills
Rapamycin (rapamune)	13 yr	Prevention of graft rejection/reduced tumor occurrence	Abnormality in wound healing/skin lesion
Rituximab	18 yr	Improved neurological symptoms/reduced recurrence of nephrotic syndrome/reduced blood CD19 (+) cell counts	Allergic reaction/infection/pancytopenia
Sildenafil	18 yr	Control of pulmonary hypertension	Retinopathy of prematurity/hypotension
Sotalol	18 yr	Control of atrial or ventricular tachycardia	Arrhythmia
Tacrolimus	12 yr	Reduced recurrence of nephrotic syndrome	Hypertension/kidney function abnormalities
Topiramate	2 yr	Decreased seizure activity	Oversedation
Valganciclovir	18 yr	Reduced length of stay/treatment of cytomegalovirus	Pancytopenia

### Review of the EMRs data and classification

We obtained a list of patients who received any of the 32 drugs between January–December 2014. Then, the investigators (doctors) at each site collected data including patient demographics, diagnoses, reasons for administration, routes of administration, and details of adverse drug reactions. Additionally, the mortality in the cohort was assessed. The age of the patients was categorized as follows: group 1, 0 days–1 month; group 2, 1–23 months; group 3, 2–11 years; and group 4, 12–18 years.

### Data processing and statistical analysis

The primary outcomes were the efficacy and safety of the drugs, including mortality. And the secondary outcomes were the current statuses of the use of off-labeled/unlicensed drugs in the two centers. Descriptive analyses were performed to analyze the continuous variables. Normality of data was tested by Kolmogorov-Smirnov test. Categorical variables are expressed

as numbers and percentages, and continuous variables as mean (standard deviation [SD]) or medians with the interquartile range. Student's t-test or Mann-Whitney rank-sum test was used to test the statistical significance of continuous data. Binary logistic regression analysis was performed to evaluate the association between parameters and adverse drug events. All analyses were performed using Excel 2013 for Windows and SPSS ver. 22 (IBM Corp., Armonk, NY, USA). A threshold of  $P < 0.05$  was set to indicate statistical significance.

### Ethics statement

This retrospective observational study was performed in two tertiary hospitals in the Republic of Korea, and approved by the Institutional Review Board of Seoul National University (H1603-086-749) and Severance Hospital (4-2016-0592). The requirement for written informed consent was waived.

## RESULTS

A total of 5,130 prescriptions in 2,779 patients with 1,325 males and 1,454 females at the two children's centers were identified. The age distribution of the patients were as follows: there were 176 (6.3%) patients in group 1, 735 in group 2, 890 (32.0%) in group 3, and 978 (35.2%) in group 4. Overall, 2,351 patients received two or more off-labeled/unlicensed drugs (84.6%) with a mean of 1.8 prescriptions per patient. Additionally, 1,136 prescriptions were from intensive care units, while 3,666 were from the wards, and 328 from the emergency departments.

The drugs qualified as off-labeled/unlicensed in terms of age as the most common reason (73.5%), followed by indication (11.7%), weight (3.6%), and route of administration (0.7%) (Table 2). The most commonly prescribed category of off-labeled/unlicensed drugs was antifungal agents (43.3%) followed by gastrointestinal drugs (23.0%), cardiovascular drugs (19.5%), analgesics (18.0%), and antiemetics (10.0%). The most frequently prescribed off-labeled/unlicensed drug as a single agent was dopamine (13.7%), followed by propacetamol (11.0%) and ramosetron (10.2%). Table 3 shows the number of prescriptions and those demonstrating the efficacy and adverse drug reactions of each drug in the study cohort.

With regard to the age of the patients, group 2 received the most number of off-label/unlicensed prescriptions (32.9%), followed by group 3 (31.1%), group 4 (29.4%), and group 1 (5.5%). In terms of the wards, 71.2% of prescriptions were from the general ward, while 22.1% were from intensive care units, and 6.4% from emergency departments. Regarding out-patient department, most of the data were excluded because the data to assess the safety

**Table 2.** The categories of off-labeled/unlicensed drugs used and their incidences

Category	Description	No. of prescription
Age	Administration of a prescription drug outside the age range for which the product was licensed	3,773 (73.5)
Route of administration	The use of alternative routes of administration other than the approved routes for that formulation stated in the Product Information	34 (0.7)
Weight	Administration of prescription drugs for weights for which the product was not licensed	183 (3.6)
Indication	Prescription of a drug for indications not described in the Product Information	598 (11.7)
Combined	Satisfies two or more criteria mentioned above	541 (10.6)
Total		5,130 (100)

Values are presented as number (%).

**Table 3.** The number of prescriptions, and outcomes regarding efficacy and side effects of each drug in the cohort

Drug name	No. of prescriptions	No. of outcomes of efficacy	No. of outcomes of side effects
Bisoprolol	11 (0.2)	8 (72.7)	3 (27.3)
Carbidopa/L-dopa	107 (2.0)	100 (93.5)	36 (33.6)
Carvedilol	199 (3.7)	188 (94.5)	10 (5.0)
Ciprofloxacin	120 (2.3)	96 (80.0)	4 (3.3)
Clobazam	31 (0.6)	28 (90.3)	2 (6.5)
Dexmedetomidine	43 (0.8)	42 (97.7)	6 (14.0)
Domperidone maleate	183 (3.4)	156 (85.2)	16 (8.7)
Dopamine	726 (13.7)	696 (95.9)	65 (9.0)
Enalapril	34 (0.6)	34 (100)	1 (2.9)
Esomeprazole magnesium trihydrate	258 (4.9)	246 (95.3)	94 (36.4)
Fentanyl	339 (6.4)	298 (87.9)	14 (4.1)
Fluconazole	80 (1.5)	72 (90.0)	9 (11.3)
Ganciclovir	111 (2.1)	105 (94.6)	51 (45.9)
Lansoprazole	385 (7.3)	313 (81.3)	49 (12.7)
Levetiracetam	22 (0.4)	21 (95.5)	3 (13.6)
Levocetirizine	23 (0.4)	13 (56.5)	5 (21.7)
Levofloxacin	21 (0.4)	11 (52.4)	1 (4.8)
Losartan	17 (0.3)	17 (100)	3 (13.6)
Metoclopramide	349 (6.6)	294 (84.2)	17 (4.9)
Mosapride	261 (4.9)	116 (44.4)	28 (10.7)
Octreotide	12 (0.2)	11 (91.7)	5 (41.7)
Pamidronate	44 (0.8)	31 (70.5)	13 (29.5)
Propacetamol	586 (11.0)	576 (98.3)	28 (4.8)
Propofol	155 (2.9)	155 (100)	11 (7.1)
Ramosetron	540 (10.2)	464 (85.9)	150 (27.8)
Rapamycin (rapamune)	11 (0.2)	9 (81.8)	0
Rituximab	76 (1.4)	72 (94.7)	15 (19.7)
Sildenafil	119 (2.2)	105 (88.2)	14 (11.8)
Sotalol	12 (0.2)	9 (81.8)	2 (16.7)
Tacrolimus	196 (3.7)	168 (85.7)	16 (8.2)
Topiramate	27 (0.5)	23 (85.2)	2 (7.4)
Valganciclovir	32 (0.6)	26 (81.3)	7 (21.9)
Total	5,310 (100)	4,503 (87.7)	680 (13.25)

Data are presented as number (%).

and efficacy were not available. Therefore, only a small proportion of prescriptions (0.8%) appear to be from the out-patient departments.

A total of 523 patient developed adverse drug reactions (18.8%). The number of prescriptions was significantly higher in children with adverse drug reactions than it was in those without adverse drug reactions (2.8 vs. 1.5; 95% confidence interval [CI], 1.0–1.5;  $P < 0.001$ ). The mean age was lower in patients with adverse drug reactions than it was in those without, but it was not statistically significant (7.5 vs. 8.0 years; 95% CI, -0.3–0.8 years;  $P = 0.08$ ).

Binary logistic regression determined that the number of prescribed off-label/unlicensed medicines and the age at prescription were independently associated with subsequent adverse drug events (odds ratio [OR], 1.55; 95% CI, 1.44–1.65;  $P < 0.001$  for the number of medicines; OR, 1.1; 95% CI, 1.0–1.2;  $P = 0.034$  for age).

Of the 2,779 patients who received off-labeled/unlicensed prescriptions, 112 patients died during the follow-up period. None of the deaths were associated with the use of off-labeled/unlicensed drugs, but they appeared to be associated with the underlying diseases. The primary diagnoses in these patients were categorized as follows: hemato-oncologic diseases (n = 37, 33%), congenital heart diseases (n = 19, 17%), airway and respiratory diseases (n = 16,

**Table 4.** The number of prescriptions, and outcomes of efficacy and side effects of each drug along with mortality

Drug name	No. of cases	No. of outcomes of efficacy	No. of outcomes of side effects
Bisoprolol	0	0	0
Carbidopa/L-dopa	1 (0.3)	0	0
Carvedilol	6 (2.0)	6 (100)	0
Ciprofloxacin	25 (8.4)	19 (76.0)	1 (4.0)
Clobazam	0	0	0
Dexmedetomidine	2 (0.7)	2 (100)	0
Domperidone maleate	7 (2.4)	5 (71.4)	0
Dopamine	93 (31.4)	73 (78.5)	4 (4.3)
Enalapril	0	0	0
Esomeprazole magnesium trihydrate	33 (11.1)	31 (93.9)	22 (66.7)
Fentanyl	20 (6.8)	19 (95.0)	1 (5.0)
Fluconazole	13 (4.4)	12 (92.3)	3 (23.1)
Ganciclovir	14 (4.7)	12 (85.7)	11 (78.6)
Lansoprazole	11 (3.7)	11 (100)	3 (27.3)
Levetiracetam	0	0	0
Levocetirizine	0	0	0
Levofloxacin	0	0	0
Losartan	0	0	0
Metoclopramide	6 (2.0)	3 (50)	2 (33.3)
Mosapride	4 (1.4)	2 (50)	1 (25.0)
Octreotide	0	0	0
Pamidronate	0	0	0
Propacetamol	11 (3.7)	10 (90.9)	3 (27.3)
Propofol	2 (0.7)	2 (100)	0
Ramosetron	24 (8.1)	23 (95.8)	9 (37.5)
Rapamycin	0	0	0
Rituximab	4 (1.4)	3 (75.0)	3 (75.0)
Sildenafil	19 (6.4)	12 (63.2)	6 (31.6)
Sotalol	0	0	0
Tacrolimus	1 (0.3)	1 (100)	0
Topiramate	0	0	0
Valganciclovir	0	0	0
Total	296 (100)	246 (83.1)	69 (23.3)

Data are presented as number (%).

14.3%), gastrointestinal diseases (n = 10, 8.9%), immunologic diseases (n = 5, 4.5%), preterm births (n = 5, 4.5%), renal and urinary tract diseases (n = 4, 3.6%), cardiovascular diseases other than congenital heart diseases (n = 3, 2.7%), cerebrovascular diseases (n = 3, 2.7%), sepsis (n = 3, 2.7%), neuromuscular diseases (n = 2, 1.8%), hormonal or metabolic diseases (n = 2, 1.8%), brain death (n = 2, 1.8%), and orthopedic diseases (n = 1, 0.9%).

A total of 296 unlabeled prescriptions were identified in these patients (an average of 2.6 prescriptions per patient). The most frequently prescribed off-labeled/unlicensed drugs were dopamine (31.4%), esomeprazole magnesium trihydrate (11.1%), ciprofloxacin (8.4%), and ramosetron (8.1%). The most frequent adverse drug reactions were hematocytopenia (n = 28), liver function abnormalities (n = 20), fever (n = 9), hypotension (n = 5), vomiting (n = 3), and headache (n = 2). The number of prescriptions, and the number of cases with outcomes of efficacy and adverse drug reactions are shown in **Table 4**.

## DISCUSSION

This retrospective observational study investigated the use of off-labeled/unlicensed medicines in two tertiary pediatric hospitals in the Republic of Korea. On an average, approximately two



off-labeled/unlicensed drugs were prescribed per patient, and the incidence of off-labeled/unlicensed prescription was higher in younger patients. The children who died had higher number of off-labeled/unlicensed prescriptions than did the total cohort.

Off-labeled/unlicensed administration of drugs in pediatric centers is common in tertiary hospitals. Several studies have investigated the use of off-label or unlicensed medicines in pediatric centers.<sup>7-10</sup> According to one study, the reported off-labeled or unlicensed prescription rates ranged from 11%–80% in different clinical settings,<sup>11</sup> while another study reported that more than 90% of children received off-label/unlicensed medicines in Norway.<sup>7</sup> In contrast to previous studies, we reviewed only the off-label prescriptions and did not include the children without off-labeled/unlicensed prescription. Therefore, we could not assess the incidence of off-label prescriptions out of the total prescriptions.

In our study, the primary reasons for off-labeled/unlicensed prescriptions were age and indications, which was a similar finding of a previous systematic review.<sup>12</sup> On the other hand, other studies reported that the route of administration was the most common reason for off-labeled/unlicensed prescriptions,<sup>7,13</sup> for example, buccal administration of sedatives and analgesics, and administration of drugs via enteral feeding tube. We believe that the differences between our study and previous reports regarding the reasons might be the differences in the route of administration in children. For example, according to Lindell-Osuagwu et al.,<sup>13</sup> buccal administration of sedatives and analgesics was the primary reason for off-labeled/unlicensed prescriptions. In the centers we investigated, buccal or nasal administration of drugs in children were rare. Additionally, off-label handling, such as tablet splitting or tablet/capsule dispersion, was typical in children. However, this type of off-label handling might be missing from EMRs.<sup>7</sup>

Of the pediatric patients who received off-labeled/unlicensed prescriptions, the children of the youngest age group received the highest number of such prescriptions in the present study. Our results were in accordance with those of previous studies,<sup>11,14</sup> demonstrating that lower the age of a child, the more likely doctors are to use off-label or unlicensed prescriptions. A more recent study also reported that most off-label prescriptions occurred in infants and children, with percentage > 60%.<sup>10</sup> On the other hand, one report from a French hospital showed that adolescents (12–18-year-old) and children (2–11-year-old) received the highest number of off-label/unlicensed prescriptions (46.8% and 45%, respectively).<sup>9</sup> However, in that study, the number of neonates and infants assessed was very small.

As single agents, dopamine and propacetamol were the most frequently prescribed medicines in this study. Dopamine has been used in the pediatric population for over 40 years.<sup>15</sup> However, according to drug information provided by the Korea MFDS, its safety and efficacy in the pediatric population has not been investigated, which was similar to the drug information provided by the US Food and Drug Administration and European Medicine Agency. Therefore, we included dopamine in the list of off-labeled/unlicensed drugs in the present study. Additionally, the use of intravenous propacetamol in neonates and children has gained popularity,<sup>16,17</sup> and it has been widely used for postoperative pain control and as an antipyretic in Korea. In US, intravenous acetaminophen is approved in children aged > 2 years. In European countries, it has been approved in children immediately after birth<sup>18</sup> and is most frequently used for analgesia in the pediatric wards in European countries.<sup>2</sup> Therefore, we believe that it is necessary to reconsider the authorization of drugs that have been used for a long time, especially when the prescription is for therapeutic use.

In this study, we intended to evaluate adverse drug reactions of the off-labeled prescriptions. There have been several reports regarding the risk assessment of off-labeled/unlicensed medicines in pediatric patients.<sup>3,19-21</sup> Two review articles investigated the rate of adverse effects associated with the use of off-label/unlicensed medicines and found that it varied from 17%–60%.<sup>21,22</sup> Other prospective studies found that the ORs of an off-labeled/unlicensed medicine being implicated in an adverse drug reaction compared with an authorized medicine, was from 1.67–2.84 in children.<sup>3,19,20</sup> A study by Bellis et al.<sup>19</sup> demonstrated that the number of off-labeled/unlicensed medicines was not a predictor of the risk of adverse drug reactions. On the other hand, Saiyed et al.<sup>3</sup> reported that the hazard of an adverse drug reaction significantly increased with the number of off-label medicines prescribed (hazard ratio of 1.28), which was a similar rate as our results. Many off-labeled drugs in children are prescribed in combination; therefore, clinicians should closely monitor the responses of children administration of such drugs.

Along with the number of off-labeled/unlicensed medicines, age was also a risk factor of adverse drug reactions in the present study. The OR was 1.1, which was similar to that reported by a previous prospective study performed in the UK (OR, 1.04).<sup>19</sup> We assume that the off-labeled/unlicensed drugs might be overused in terms of frequency or doses in older children or adolescents, whereas clinicians should be more careful when treating infants or neonates. However, careful interpretation is required for this result. This was a retrospective study; therefore, the outcomes may be affected by confounding factors after drug administration, such as the severity of illness or conditions that require surgery. For example, increasing age was a risk factor for adverse drug events in oncologic patients, but not in non-oncologic patients.<sup>19</sup> Additionally, there was difficulty in distinguishing the symptoms due to the underlying pathologies and adverse drug reactions in some patients.

Although children with mortality received a relatively greater number of off-labeled/unlicensed medicines than children without mortality (2.6 vs. 1.6 per pediatric patient), the authors could not determine a definite association between the use of medicines and death because the children had wide range of disease conditions at various stages. In the present study, the hemato-oncologic disease was the most common diagnosis in children with mortality. This result is similar to a recent study by Kim et al.,<sup>23</sup> demonstrating that malignancy was the most common cause of death in children with complex chronic conditions in Korea. Disease severity might be related to the amount of medication used, including off-label medicine use. Further study should focus on the efficacy and safety of off-label/unlicensed medicine usage within a similar patient population.

Our study has several limitations. First, we did not evaluate the total prescriptions of all medicines in the same period; therefore, the incidence of off-label prescriptions could not be calculated. Second, the efficacy and safety of medicines prescribed to outpatients could not be evaluated well due to a lack of EMR regarding the follow-up information. Third, the drugs prescribed solely in children who required chemotherapy could not be evaluated; it was difficult to determine the adverse drug reactions of each anticancer drug because many off-label drugs were administered simultaneously. Additionally, the short-term response after anticancer drug administration was hard to predict in children who underwent chemotherapy. The anticancer medications were mostly prescribed for treatment, i.e., there were no other drug options for those patients. Finally, the implications of off-labeled/unlicensed use might be more important when considering the long-term adverse events, as well as immediate ones, especially in children. For example, the overuse or underuse of



cardiovascular drugs such as dopamine and milrinone may result in hemodynamic instability and related sequelae.<sup>24</sup> However, the safety assessment was mainly focused on the short-term adverse drug events in our study.

In summary, this study demonstrated the off-labeled/unlicensed drug use in children in tertiary hospitals in Korea and evaluated the safety of drugs retrospectively. Children continue to receive medicines that were not authorized in terms of age, weight, indication, or route of administration. Therefore, many old products require re-assessment of authorization. Adverse drug reactions are still associated with the use of these drugs. Additionally, the labelling of drugs differs between countries. Therefore, further prospective clinical studies are needed to confirm the efficacy and safety of drugs in the pediatric population. Additionally, efforts by pediatricians and regulatory authorities are needed to improve pediatric drug labelling.

## REFERENCES

1. Joseph PD, Craig JC, Caldwell PH. Clinical trials in children. *Br J Clin Pharmacol* 2015;79(3):357-69.  
[PUBMED](#) | [CROSSREF](#)
2. Conroy S, Choonara I, Impicciatore P, Mohn A, Arnell H, Rane A, et al. Survey of unlicensed and off label drug use in paediatric wards in European countries. *BMJ* 2000;320(7227):79-82.  
[PUBMED](#) | [CROSSREF](#)
3. Saiyed MM, Lalwani T, Rana D. Is off-label use a risk factor for adverse drug reactions in pediatric patients? A prospective study in an Indian tertiary care hospital. *Int J Risk Saf Med* 2015;27(1):45-53.  
[PUBMED](#)
4. Clavenna A, Bonati M. Adverse drug reactions in childhood: a review of prospective studies and safety alerts. *Arch Dis Child* 2009;94(9):724-8.  
[PUBMED](#) | [CROSSREF](#)
5. Kimland E, Nydert P, Odland V, Böttiger Y, Lindemalm S. Paediatric drug use with focus on off-label prescriptions at Swedish hospitals - a nationwide study. *Acta Paediatr* 2012;101(7):772-8.  
[PUBMED](#) | [CROSSREF](#)
6. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. *Lancet* 2000;356(9237):1255-9.  
[PUBMED](#) | [CROSSREF](#)
7. Teigen A, Wang S, Truong BT, Bjercknes K. Off-label and unlicensed medicines to hospitalised children in Norway. *J Pharm Pharmacol* 2017;69(4):432-8.  
[PUBMED](#) | [CROSSREF](#)
8. Kimland E, Odland V. Off-label drug use in pediatric patients. *Clin Pharmacol Ther* 2012;91(5):796-801.  
[PUBMED](#) | [CROSSREF](#)
9. Joret-Descout P, Prot-Labarthe S, Brion F, Bataille J, Hartmann JF, Bourdon O. Off-label and unlicensed utilisation of medicines in a French paediatric hospital. *Int J Clin Pharm* 2015;37(6):1222-7.  
[PUBMED](#) | [CROSSREF](#)
10. Czarniak P, Bint L, Favié L, Parsons R, Hughes J, Sunderland B. Clinical setting influences off-label and unlicensed prescribing in a paediatric teaching hospital. *PLoS One* 2015;10(3):e0120630.  
[PUBMED](#) | [CROSSREF](#)
11. Pandolfini C, Bonati M. A literature review on off-label drug use in children. *Eur J Pediatr* 2005;164(9):552-8.  
[PUBMED](#) | [CROSSREF](#)
12. Magalhães J, Rodrigues AT, Roque F, Figueiras A, Falcão A, Herdeiro MT. Use of off-label and unlicensed drugs in hospitalised paediatric patients: a systematic review. *Eur J Clin Pharmacol* 2015;71(1):1-13.  
[PUBMED](#) | [CROSSREF](#)
13. Lindell-Osuagwu L, Hakkarainen M, Sepponen K, Vainio K, Naaranlahti T, Kokki H. Prescribing for off-label use and unauthorized medicines in three paediatric wards in Finland, the status before and after the European Union Paediatric Regulation. *J Clin Pharm Ther* 2014;39(2):144-53.  
[PUBMED](#) | [CROSSREF](#)

14. Ribeiro M, Jorge A, Macedo AF. Off-label drug prescribing in a Portuguese paediatric emergency unit. *Int J Clin Pharm* 2013;35(1):30-6.  
[PUBMED](#) | [CROSSREF](#)
15. Driscoll DJ, Gillette PC, McNamara DG. The use of dopamine in children. *J Pediatr* 1978;92(2):309-14.  
[PUBMED](#) | [CROSSREF](#)
16. Palmer GM, Chen SP, Smith KR, Hardikar W. Introduction and audit of intravenous paracetamol at a tertiary paediatric teaching hospital. *Anaesth Intensive Care* 2007;35(5):702-6.  
[PUBMED](#)
17. Murat I, Baujard C, Foussat C, Guyot E, Petel H, Rod B, et al. Tolerance and analgesic efficacy of a new i.v. paracetamol solution in children after inguinal hernia repair. *Paediatr Anaesth* 2005;15(8):663-70.  
[PUBMED](#) | [CROSSREF](#)
18. de Martino M, Chiarugi A. Recent advances in pediatric use of oral paracetamol in fever and pain management. *Pain Ther* 2015;4(2):149-68.  
[PUBMED](#) | [CROSSREF](#)
19. Bellis JR, Kirkham JJ, Nunn AJ, Pirmohamed M. Adverse drug reactions and off-label and unlicensed medicines in children: a prospective cohort study of unplanned admissions to a paediatric hospital. *Br J Clin Pharmacol* 2014;77(3):545-53.  
[PUBMED](#) | [CROSSREF](#)
20. Bellis JR, Kirkham JJ, Thiesen S, Conroy EJ, Bracken LE, Mannix HL, et al. Adverse drug reactions and off-label and unlicensed medicines in children: a nested case-control study of inpatients in a pediatric hospital. *BMC Med* 2013;11(1):238.  
[PUBMED](#) | [CROSSREF](#)
21. Mason J, Pirmohamed M, Nunn T. Off-label and unlicensed medicine use and adverse drug reactions in children: a narrative review of the literature. *Eur J Clin Pharmacol* 2012;68(1):21-8.  
[PUBMED](#) | [CROSSREF](#)
22. Cuzzolin L, Atzei A, Fanos V. Off-label and unlicensed prescribing for newborns and children in different settings: a review of the literature and a consideration about drug safety. *Expert Opin Drug Saf* 2006;5(5):703-18.  
[PUBMED](#) | [CROSSREF](#)
23. Kim MS, Lim NG, Kim HJ, Kim C, Lee JY. pediatric deaths attributed to complex chronic conditions over 10 years in Korea: evidence for the need to provide pediatric palliative care. *J Korean Med Sci* 2018;33(1):e1.  
[PUBMED](#) | [CROSSREF](#)
24. Czaja AS, Reiter PD, Schultz ML, Valuck RJ. Patterns of off-label prescribing in the pediatric intensive care unit and prioritizing future research. *J Pediatr Pharmacol Ther* 2015;20(3):186-96.  
[PUBMED](#)